Opinion|Videos|January 12, 2024
IsKia: Isatuximab Plus KRd in Pre-Transplant Induction and Post-Transplant Consolidation in TE NDMM
Larry Anderson, MD, goes over the recent data from the IsKia trial which investigated IsaKRd in pre-transplant induction and post-transplant consolidation in TE NDMM.
Advertisement
Episodes in this series
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera
3
PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer
4
Distinguishing HER2 Mutations From Amplification in NSCLC Testing
5